D
David M. Donovan
Researcher at United States Department of Agriculture
Publications - 95
Citations - 4578
David M. Donovan is an academic researcher from United States Department of Agriculture. The author has contributed to research in topics: Lysin & Bacteriophage. The author has an hindex of 38, co-authored 94 publications receiving 3961 citations. Previous affiliations of David M. Donovan include Agricultural Research Service.
Papers
More filters
Journal ArticleDOI
Bacteriophage endolysins as novel antimicrobials
TL;DR: The modular structure of endolysins is reviewed, in which cell wall binding and catalytic functions are separated, as well as their mechanism of action, lytic activity and potential as antimicrobials.
Book ChapterDOI
Endolysins as antimicrobials.
Daniel C. Nelson,Mathias Schmelcher,Lorena Rodríguez-Rubio,Jochen Klumpp,David G. Pritchard,Shengli Dong,David M. Donovan +6 more
TL;DR: This chapter includes relevant studies of other well-characterized PG hydrolase antimicrobials, including bacteriophage endolysins, which are believed refractory to resistance development.
Journal ArticleDOI
Antimicrobial bacteriophage-derived proteins and therapeutic applications.
Dwayne R. Roach,David M. Donovan +1 more
TL;DR: The current preclinical state of using phage-derived endolysins, virion-associated peptidoglycan hydrolases, polysaccharide depolymerases, and holins for the treatment of bacterial infection is reviewed.
Journal ArticleDOI
The phage K lytic enzyme LysK and lysostaphin act synergistically to kill MRSA
TL;DR: In this article, the optimal reaction conditions for the recombinant His-tagged LysK protein (pH range pH 6-10, and 0.3-0.5 M NaCl), and C-His-LysK MIC (32.85+/-4.87 mug mL(-1)).
Journal ArticleDOI
Alternatives to antibiotics: a symposium on the challenges and solutions for animal production
TL;DR: The objectives of the symposium ‘Alternatives to Antibiotics’ were to highlight promising research results and novel technologies that could potentially lead to alternatives to conventional antibiotics, and assess challenges associated with their commercialization, and provide actionable strategies to support development of alternative antimicrobials.